Dr. Mease et al reply
J Rheumatol
.
2021 Dec;48(12):1891-1892.
doi: 10.3899/jrheum.210750.
Epub 2021 Sep 1.
Authors
Philip J Mease
1
,
Robert R McLean
2
,
Blessing Dube
2
,
Mei Liu
2
,
Sabrina Rebello
2
,
Meghan Glynn
2
,
Esther Yi
3
,
Yujin Park
3
,
Alexis Ogdie
4
Affiliations
1
Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, Washington; pmease@philipmease.com.
2
CorEvitas, LLC, Waltham, Massachusetts.
3
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
4
Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
PMID:
34470796
DOI:
10.3899/jrheum.210750
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antirheumatic Agents*
Humans
Substances
Antirheumatic Agents